Business
LivaNova Reports First-Quarter 2025 Results; Updates 2025 Guidance
Delivered high-single-digit revenue growth, double-digit organic revenue growth, and continued operating margin expansion Raised full-year 2025 revenue
About this update from Livanova Plc
[{"type":"text","content":"\n\nDelivered high-single-digit revenue growth, double-digit organic revenue growth, and continued operating margin expansion\n\n\nRaised full-year 2025 revenue guidance; updated full-year 2025 guidance now incorporates impact of SNIA decision and currently applicable tariffs\n\n\nCompleted premarket approval submission for the aura6000™ System intended to treat obstructive sleep apnea\n\n\nAnnounced 12-month, top-line OSPREY data demonstrating strong response and sustained therapeutic impact for patients who received proximal hypoglossal nerve stimulation for obstructive sleep apnea\n\n\n LONDON--(BUSINESS WIRE)--\nLivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, today reported results for the first quarter ended March 31, 2025 and updated full-year 2025 guidance.\n\nFinancial Summary and Highlights(1)\n\n\nFirst-quarter revenue of $316.9 million increased 7.4% on a reported basis, 8.9% on a constant-currency basis, and 10.4% on an organic basis as compared to the prior-year period\n\n\nFirst-quarter U.S. GAAP diluted loss per share of $6.01, impacted by recording SNIA environmental liability of €333.3 million ($360.4 million as of March 31, 2025), and adjusted diluted earnings per share of $0.88\n\n\nFirst-quarter net cash provided by operating activities of $24.0 million and adjusted free cash flow of $20.0 million\n\n\nRaised full-year 2025 revenue growth range 100 basis points to 6.0% to 7.0% on a constant-currency basis and 7.0% to 8.0% on an organic basis. Revised full-year 2025 adjusted diluted earnings per share range to $3.60 to $3.70, which now incorporates the impact of the SNIA decision and currently applicable tariffs. Adjusted free cash flow is expected to be in the range of $135 million to $155 million, consistent with prior guidance\n\n\nCompleted premarket approval (PMA) submission to the U.S. Food and Drug Administration for the aura6000™ System, supported by achieving the primary safety and efficacy endpoints in the OSPREY trial\n\n\nAnnounced 12-month, top-line data from the OSPREY trial demonstrating strong response and durability of therapy for patients who received proximal hypoglossal nerve stimulation, including those with severe obstructive sleep apnea, elevated body mass index, and high risk of complete concentric collapse: at 12 months of therapy, the active patient responder...